Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results
|
ENDRA Life Sciences Inc. (NDRA)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/14/2023 |
8-K
| Quarterly results |
11/14/2022 |
8-K
| Quarterly results |
08/15/2022 |
8-K
| Quarterly results |
05/12/2022 |
8-K
| Quarterly results |
03/30/2022 |
8-K
| Quarterly results |
11/15/2021 |
8-K
| Quarterly results |
08/12/2021 |
8-K
| Quarterly results |
05/17/2021 |
8-K
| Quarterly results |
03/25/2021 |
8-K
| Quarterly results |
11/16/2020 |
8-K
| Quarterly results |
08/17/2020 |
8-K
| Quarterly results |
05/14/2020 |
8-K
| Quarterly results |
03/26/2020 |
8-K
| Quarterly results |
11/13/2019 |
8-K
| Quarterly results |
03/11/2019 |
8-K
| Quarterly results |
03/20/2018 |
8-K
| Quarterly results
Docs:
|
"ENDRA Life Sciences Inc. Consolidated Balance Sheets December 31, December 31, Assets 2017 2016 Assets Cash $5,601,878 $144,953 Accounts receivable 6,850 - Prepaid expenses 67,497 - Inventory 191,680 40,105 Other current assets 14,249 10,535 Total Current Assets 5,882,154 195,594 Other Assets Fixed assets, net 241,549 295,168 Total Assets $6,123,702 $490,761 Liabilities and Stockholders’ Equity Current Liabilities: Accounts payable and accrued liabilities $848,214 $434,552 Notes payable - 50,000 Convertible notes payable, related party, net of discount - 99,804 Convertible notes payable, net of discount - 800,172 Total Current Liabilities 848,214 1,384,528 Total Liabilities 848,214 1,384,528 Stockholders’ Equity Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares is..." |
|
11/15/2017 |
8-K
| Quarterly results |
|
|